BR112020016613A2 - Composições para o tratamento de doença hepática gordurosa não alcóolica e esteato-hepatite não alcoólica - Google Patents

Composições para o tratamento de doença hepática gordurosa não alcóolica e esteato-hepatite não alcoólica Download PDF

Info

Publication number
BR112020016613A2
BR112020016613A2 BR112020016613-8A BR112020016613A BR112020016613A2 BR 112020016613 A2 BR112020016613 A2 BR 112020016613A2 BR 112020016613 A BR112020016613 A BR 112020016613A BR 112020016613 A2 BR112020016613 A2 BR 112020016613A2
Authority
BR
Brazil
Prior art keywords
drug
ibutamoren
fact
effective amount
therapeutically effective
Prior art date
Application number
BR112020016613-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael Oliver Thorner
Roy G. Smith
Original Assignee
Lumos Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lumos Pharma, Inc. filed Critical Lumos Pharma, Inc.
Publication of BR112020016613A2 publication Critical patent/BR112020016613A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112020016613-8A 2018-02-14 2019-02-14 Composições para o tratamento de doença hepática gordurosa não alcóolica e esteato-hepatite não alcoólica BR112020016613A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862630361P 2018-02-14 2018-02-14
US62/630,361 2018-02-14
PCT/US2019/017964 WO2019161025A1 (en) 2018-02-14 2019-02-14 Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Publications (1)

Publication Number Publication Date
BR112020016613A2 true BR112020016613A2 (pt) 2020-12-22

Family

ID=67620042

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020016613-8A BR112020016613A2 (pt) 2018-02-14 2019-02-14 Composições para o tratamento de doença hepática gordurosa não alcóolica e esteato-hepatite não alcoólica

Country Status (10)

Country Link
US (3) US20210059993A1 (https=)
EP (3) EP4623929A3 (https=)
JP (3) JP2021513552A (https=)
KR (2) KR20200121308A (https=)
CN (2) CN118453597A (https=)
AU (2) AU2019222736B2 (https=)
BR (1) BR112020016613A2 (https=)
CA (1) CA3088177A1 (https=)
EA (1) EA202091464A1 (https=)
WO (1) WO2019161025A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113646327A (zh) * 2019-03-29 2021-11-12 综合医院公司 用于治疗肝脏疾病的ghrh或其类似物
WO2022059946A1 (ko) * 2020-09-18 2022-03-24 서울대학교 산학협력단 비알코올성 지방간염 및 간 섬유화의 치료를 위한 약학적 조성물
KR20220132312A (ko) 2021-03-23 2022-09-30 한국과학기술원 간세포의 IFN-γR1 매개 지질생성작용 억제를 통한 비알코올성 지방간 질환의 치료 방법
KR20250107210A (ko) * 2022-11-03 2025-07-11 루모스 파마, 인크. 이부타모렌의 압축형 경구 제형
WO2025193784A1 (en) * 2024-03-12 2025-09-18 Lumos Pharma, Inc. Pharmaceutical formulations for maintaining lean muscle mass during weight loss treatment
WO2025217521A1 (en) * 2024-04-12 2025-10-16 Jnana Therapeutics Inc. Treating chronic kidney disease with a combination of a slc6a19 inhibitor and a glp-1 agonist
CN119405782A (zh) * 2025-01-06 2025-02-11 山东大学 胰岛素样生长因子结合蛋白-1在制备治疗非酒精性脂肪性肝病药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US20070123470A1 (en) * 2003-10-24 2007-05-31 Wladimir Hogenhuis Enhancement of growth hormone levels with a dipeptidyl peptidase IV inhibitor and a growth hormone secretagogue
JP2007532495A (ja) * 2004-04-07 2007-11-15 ガストロテック・ファルマ・アクティーゼルスカブ グレリン欠乏を治療するための分泌促進薬の使用
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
BR112017004708A2 (pt) * 2014-09-12 2017-12-05 Tobira Therapeutics Inc terapia de combinação de cenicriviroc para o tratamento de fibrose
US20180360846A1 (en) * 2015-09-16 2018-12-20 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
WO2019008554A1 (en) * 2017-07-06 2019-01-10 Conte Anthony METHOD FOR ORAL TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE

Also Published As

Publication number Publication date
JP2025179056A (ja) 2025-12-09
US20250281470A1 (en) 2025-09-11
EP4623929A2 (en) 2025-10-01
CA3088177A1 (en) 2019-08-22
EP4623929A3 (en) 2025-12-17
EP3781158A1 (en) 2021-02-24
EP4467158A2 (en) 2024-11-27
AU2019222736B2 (en) 2024-08-01
WO2019161025A1 (en) 2019-08-22
JP2021513552A (ja) 2021-05-27
AU2019222736A1 (en) 2020-07-30
EA202091464A1 (ru) 2020-12-07
CN118453597A (zh) 2024-08-09
KR20200121308A (ko) 2020-10-23
US20210059993A1 (en) 2021-03-04
EP3781158A4 (en) 2022-03-16
CN111727041A (zh) 2020-09-29
KR20240015742A (ko) 2024-02-05
EP4467158A3 (en) 2025-02-19
US20230381158A1 (en) 2023-11-30
AU2024205599A1 (en) 2024-08-22
JP2024028337A (ja) 2024-03-04

Similar Documents

Publication Publication Date Title
BR112020016613A2 (pt) Composições para o tratamento de doença hepática gordurosa não alcóolica e esteato-hepatite não alcoólica
US7834056B2 (en) Pharmaceutical composition for gout
CN1178696C (zh) 含人体生长激素和皮质甾醇合成抑制剂的用于治疗代谢综合症的制剂
JP2002501027A (ja) 高インスリン血症、高アンドロジェン症、高脂質血症および／または無排卵症を特徴とする代謝性疾患を処置するための、ｄ型イノシトールを含む組成物
JP2013537545A (ja) 筋萎縮性側索硬化症（ａｌｓ）の治療に用いるためのジアゾキシド
WO2019160057A1 (ja) 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
Page-Wilson et al. Hypothalamic obesity in patients with craniopharyngioma: treatment approaches and the emerging role of gastric bypass surgery
BR112020013733A2 (pt) composições e métodos para tratar doenças metabólicas
JP2024521091A (ja) 褐色脂肪生成を誘導する方法及び組成物
JP2019501113A (ja) 脂肪肝に伴う希発排卵の治療
CN101631558A (zh) 基于艾塞那肽和达拉根的用于治疗糖尿病的药物、其用途和治疗模式
BR112020018362A2 (pt) Composição de glp-1 para tratar obesidade e controle de peso
HK40034973A (en) Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
US20260069586A1 (en) Methods for reducing weight and preserving or increasing tissue lean mass in patients suffering from cushing's syndrome
LIN et al. An open, phase III study of lanreotide (Somatuline PR®) in the treatment of acromegaly
Chernausek Treatment of insulin-like growth factor deficiency with IGF-I: studies in humans
US20260053769A1 (en) Uses of selective androgen receptor modulator (sarm) compounds for quality weight loss
Lu et al. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism
US20260069564A1 (en) Compositions comprising selective androgen receptor modulator compounds in combination with weight loss drugs and uses thereof for quality weight loss
US20250228804A1 (en) Uses of selective androgen receptor modulator (sarm) compounds for quality weight loss
WO2026063508A1 (ja) 医薬組成物
WO2025124473A1 (zh) Glp-1类似物治疗代谢疾病的方法及医药用途
WO2026038132A1 (en) Use of gpr119 agonists for the treatment of weight related disorders
CN121969358A (zh) 选择性雄激素受体调节剂（sarm）化合物在长期体重管理中的用途
WO2026046202A1 (zh) Glp-1/gip肽或含有其的药物组合物的用途

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]